DrugPatentWatch Database Preview
CHANTIX Drug Profile
Which patents cover Chantix, and what generic alternatives are available?
Chantix is a drug marketed by Pf Prism Cv and is included in one NDA. There are three patents protecting this drug and one Paragraph IV challenge.
This drug has one hundred and eighty-three patent family members in fifty-seven countries.
The generic ingredient in CHANTIX is varenicline tartrate. There are twelve drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the varenicline tartrate profile page.
Summary for CHANTIX
| International Patents: | 183 |
| US Patents: | 3 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 8 |
| Bulk Api Vendors: | 68 |
| Clinical Trials: | 68 |
| Patent Applications: | 4 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for CHANTIX |
| Drug Sales Revenues: | Drug sales revenues for CHANTIX |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for CHANTIX |
| DailyMed Link: | CHANTIX at DailyMed |
Generic Entry Opportunity Date for CHANTIX
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Pharmacology for CHANTIX
| Drug Class | Partial Cholinergic Nicotinic Agonist |
| Mechanism of Action | Partial Cholinergic Nicotinic Agonists |
Medical Subject Heading (MeSH) Categories for CHANTIX
Synonyms for CHANTIX
| (2S,3S)-2,3-dihydroxybutanedioic acid; 5,8,14-triazatetracyclo[10.3.1.0^{2,11}.0^{4,9}]hexadeca-2(11),3,5,7,9-pentaene |
| (6R,10S)-7,8,9,10-tetrahydro-6H-6,10-methanoazepino[4,5-g]quinoxaline (2R,3R)-2,3-dihydroxysuccinate |
| 375815-87-5 |
| 5,8,14-triazatetracyclo[10.3.1.02,11.04,9]-hexadeca-2(11),3,5,7,9-pentaene L-tartrate |
| 6,10-Methano-6H-pyrazino(2,3-h)(3)benzazepine, 7,8,9,10-tetrahydro-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) |
| 7,8,9,10-Tetrahydro-6,10-methano-6H-pyrazino(2,3-h)(3)benzazepine (2R,3R)-2,3-dihydroxybutanedioate |
| 7,8,9,10-Tetrahydro-6,10-methano-6H-pyrazino[2,3-h][3]benzazepine tartrate |
| 7,8,9,10-Tetrahydro-6H-6,10-methanoazepino-[4,5-g]quinoxaline (2R,3R)-2,3-dihydroxysuccinate |
| 7,8,9,10-tetrahydro-6H-6,10-methanoazepino[4,5-g]quinoxalin-8-ium (2R,3R)-3-carboxy-2,3-dihydroxypropanoate |
| 7,8,9,10-tetrahydro-6H-6,10-methanoazepino[4,5-g]quinoxaline (2R,3R)-2,3-dihydroxysuccinate |
| 7,8,9,10-tetrahydro-6H-6,10-methanoazepino[4,5-g]quinoxaline (2R,3R)-2,3-dihydroxysuccinic acid |
| 7,8,9,10-tetrahydro-6H-6,10-methanoazepino[4,5-g]quinoxaline (2S,3S)-2,3-dihydroxysuccinate |
| 7,8,9,10-tetrahydro-6h-6,10-methanoazepino[4,5-g]quinoxaline 2,3-dihydroxybutanedioate(1:1) |
| 815V875 |
| 82269ASB48 |
| A21286 |
| AB2000110 |
| AC1L55H3 |
| AC1Q5QUE |
| AKOS005146509 |
| AKOS025311300 |
| AKOS026750167 |
| AN-6400 |
| AOB5603 |
| API0006308 |
| AS-35136 |
| BC630727 |
| C13H13N3.C4H6O6 |
| CAS-375815-87-5 |
| CCG-221351 |
| Champix |
| Champix tartrate |
| Chantix tartrate |
| Chantix; Champix; CP 526555-18 |
| Chantix;Champix |
| CHEBI:84507 |
| CHEMBL1201135 |
| CP 526555-18 |
| CP-526,555-18 |
| CP-526555-18 |
| CS-0830 |
| D06282 |
| DSSTox_CID_28998 |
| DSSTox_GSID_49072 |
| DSSTox_RID_83263 |
| DTXSID0049072 |
| FT-0675785 |
| HMS3260I15 |
| HY-10021 |
| I14-8434 |
| LS-186594 |
| MolPort-009-682-971 |
| MolPort-023-220-723 |
| NCGC00260732-01 |
| PubChem18805 |
| PubChem18821 |
| Q-101415 |
| s1440 |
| SB17431 |
| SC-24629 |
| SCHEMBL224852 |
| Tox21_113630 |
| Tox21_500047 |
| TWYFGYXQSYOKLK-LREBCSMRSA-N |
| UNII-82269ASB48 |
| Varenicline (Tartrate) |
| varenicline monotartrate |
| Varenicline tartrate |
| Varenicline tartrate (JAN/USAN) |
| Varenicline tartrate [USAN] |
| Varenicline Tartrate 1.0 mg/ml in Methanol (as free base) |
| Varenicline tartrate solution, 500 mug/mL in methanol (as free base), ampule of 1 mL, certified reference material |
| Varenicline tartrate, >=98% (HPLC) |
| Varenicline Tartrate|375815-87-5|Champix tartrate|Chantix tartrate |
| X1052 |
| X4690 |
| Z1642292115 |
US Patents and Regulatory Information for CHANTIX
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pf Prism Cv | CHANTIX | varenicline tartrate | TABLET;ORAL | 021928-001 | May 10, 2006 | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | Y | ➤ Sign Up | |||
| Pf Prism Cv | CHANTIX | varenicline tartrate | TABLET;ORAL | 021928-001 | May 10, 2006 | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Pf Prism Cv | CHANTIX | varenicline tartrate | TABLET;ORAL | 021928-001 | May 10, 2006 | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
Paragraph IV (Patent) Challenges for CHANTIX
| Drugname | Dosage | Strength | RLD | Date |
|---|---|---|---|---|
| ➤ Subscribe | Tablets | 0.5 mg and 1 mg | ➤ Subscribe | ➤ Sign Up |
International Patents for CHANTIX
Supplementary Protection Certificates for CHANTIX
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1044189 | SPC021/2008 | Ireland | ➤ Sign Up | SPC021/2008: 20081105, EXPIRES: 20210925 |
| 1044189 | C01044189/01 | Switzerland | ➤ Sign Up | PRODUCT NAME: VARENICLIN; REGISTRATION NUMBER/DATE: SWISSMEDIC 57736 21.12.2006 |
| 1044189 | 122008000038 | Germany | ➤ Sign Up | PRODUCT NAME: VARENICLIN GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH ANNEHMBAREN SALZES UNTER EINSCHLUSS VON TARTRAT; REGISTRATION NO/DATE: EU/1/06/360/001-010 20060926 |
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
